[Failure Mode and Effects Analysis (FMEA) method applied to anticoagulation of patients with non-valvular atrial fibrillation].

El método AMFE (Análisis Modal de Fallos y Efectos) aplicado a la anticoagulación de pacientes con fibrilación auricular no valvular.

Journal

Semergen
ISSN: 1578-8865
Titre abrégé: Semergen
Pays: Spain
ID NLM: 9610769

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 26 02 2018
revised: 10 04 2018
accepted: 26 04 2018
pubmed: 26 12 2018
medline: 19 12 2019
entrez: 26 12 2018
Statut: ppublish

Résumé

To contribute to the improvement of the process of anticoagulation in patients with nonvalvular atrial fibrillation (NVAF) through awareness and training activities for Primary Care Physicians. A total of 38 focus groups, sequenced according to an adaptation of the Failure Mode and Effects Analysis (FMEA) method. Each meeting was driven by «brainstorming» methodology. The geographical representation was homogeneous, with a total of 482 national. physicians (444 Primary Care Physicians, and 38 cardiologists). The meetings were held between March 28 and June 20, 2017. The main unsafe actions that can lead to a haemorrhagic or thrombotic event are incorrect anticoagulation or lack of patient follow-up. These events are mainly caused by training deficiencies in the management of NVAF, or by not taking into account possible interactions with vitamin K antagonist drugs. The main recommendations to alleviate these failures were focused on a good follow-up of patients with NVAF, on creating or updating the protocols or clinical practice guidelines, and on promoting the continuous training of physicians who usually manage patients with non-valvular AF treated with oral anticoagulants. A significant percentage of patients with NVAF are not correctly anticoagulated. Specific actions are required to alleviate this problem. Among them, the importance of a general anticoagulation training was emphasised, and particularly, the use of direct oral anticoagulants.

Identifiants

pubmed: 30584032
pii: S1138-3593(18)30427-1
doi: 10.1016/j.semerg.2018.04.011
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

spa

Sous-ensembles de citation

IM

Pagination

169-179

Informations de copyright

Copyright © 2018 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

F Atienza-Martín (F)

Unidad de Gestión Clínica M.ª Fuensanta Pérez Quirós, Distrito Sanitario Sevilla, Sevilla, España. Electronic address: fatienzam@hotmail.com.

V Barrios (V)

Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España.

M I Egocheaga (MI)

Centro de Salud Isla de Oza, Distrito Sanitario Moncloa-Fuencarral, Madrid, España.

R Hidalgo (R)

Unidad de Gestión Clínica de Cardiología y Cirugía Cardiovascular, Hospital Universitario Virgen de Macarena, Sevilla, España.

N Marín-Montañés (N)

Bayer España, Sant Joan Despí, Barcelona, España.

C Ramis (C)

GOC Networking, Barcelona, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH